Gene · 92521
Papers3,158
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,281 to 1,300 of 3,158
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| SARS-CoV-2 in residential rooms of two self-isolating persons with COVID-19. | J Aerosol Sci | 2022 | 34483358 | PubTator, text mining | PubMed |
| Drug Repurposing for the SARS-CoV-2 Papain-Like Protease. | ChemMedChem | 2022 | 34423563 | PubTator, text mining | PubMed |
| Evaluating Stability and Activity of SARS-CoV-2 PLpro for High-throughput Screening of Inhibitors. | Mol Biotechnol | 2022 | 34420183 | PubTator, text mining | PubMed |
| Blood DNA methylation profiles improve breast cancer prediction. | Mol Oncol | 2022 | 34411412 | PubTator, text mining | PubMed |
| Target-Based In Silico Screening for Phytoactive Compounds Targeting SARS-CoV-2. | Interdiscip Sci | 2022 | 34308530 | PubTator, text mining | PubMed |
| Potential phytochemical inhibitors of SARS-CoV-2 helicase Nsp13: a molecular docking and dynamic simulation study. | Mol Divers | 2022 | 34117992 | PubTator, text mining | PubMed |
| Flavonoids are promising safe therapy against COVID-19. | Phytochem Rev | 2022 | 34054380 | PubTator, text mining | PubMed |
| Evaluation of potency of the selected bioactive molecules from Indian medicinal plants with MPro of SARS-CoV-2 through in silico analysis. | J Ayurveda Integr Med | 2022 | 34054246 | PubTator, text mining | PubMed |
| Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors. | J Med Chem | 2022 | 33891389 | PubTator, text mining | PubMed |
Identifying structural-functional analogue of GRL0617, the only well-established inhibitor for papain-like protease (PLpro) of SARS-CoV2 from the pool of fungal metabolites using docking and molecular dynamics simulation. | Mol Divers | 2022 | 33825097 | PubTator, text mining | PubMed |
| Design and in silico study of the novel coumarin derivatives against SARS-CoV-2 main enzymes. | J Biomol Struct Dyn | 2022 | 33357038 | PubTator, text mining | PubMed |
| Depicting the inhibitory potential of polyphenols from Isatis indigotica root against the main protease of SARS CoV-2 using computational approaches. | J Biomol Struct Dyn | 2022 | 33292085 | PubTator, text mining | PubMed |
| Reprofiling of approved drugs against SARS-CoV-2 main protease: an in-silico study. | J Biomol Struct Dyn | 2022 | 33179586 | PubTator, text mining | PubMed |
| In-silico screening of plant-derived antivirals against main protease, 3CLpro and endoribonuclease, NSP15 proteins of SARS-CoV-2. | J Biomol Struct Dyn | 2022 | 32896226 | PubTator, text mining | PubMed |
| Four-dimensional NOE-NOE spectroscopy of SARS-CoV-2 Main Protease to facilitate resonance assignment and structural analysis. | Magn Reson (Gott) | 2021 | 37904772 | PubTator, text mining | PubMed |
| Ligand-based design, molecular dynamics and ADMET studies of suggested SARS-CoV-2 Mpro inhibitors. | RSC Adv | 2021 | 35747608 | PubTator, text mining | PubMed |
| Reduced subgenomic RNA expression is a molecular indicator of asymptomatic SARS-CoV-2 infection. | Commun Med (Lond) | 2021 | 35602196 | PubTator, text mining | PubMed |
| Chemical constituents from Limonium tubiflorum and their in silico evaluation as potential antiviral agents against SARS-CoV-2. | RSC Adv | 2021 | 35495487 | PubTator, text mining | PubMed |
| Latin American databases of natural products: biodiversity and drug discovery against SARS-CoV-2. | RSC Adv | 2021 | 35481202 | PubTator, text mining | PubMed |
| A review on potential of natural products in the management of COVID-19. | RSC Adv | 2021 | 35479175 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/92521/papers?page=65